NMRA Stock Overview
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases.
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Neumora Therapeutics, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$9.25 |
52 Week High | US$21.00 |
52 Week Low | US$8.82 |
Beta | 0 |
1 Month Change | -30.45% |
3 Month Change | -39.78% |
1 Year Change | n/a |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -43.08% |
Recent News & Updates
Shareholder Returns
NMRA | US Pharmaceuticals | US Market | |
---|---|---|---|
7D | 1.1% | 1.1% | 0.7% |
1Y | n/a | 9.5% | 23.9% |
Return vs Industry: Insufficient data to determine how NMRA performed against the US Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how NMRA performed against the US Market.
Price Volatility
NMRA volatility | |
---|---|
NMRA Average Weekly Movement | 10.3% |
Pharmaceuticals Industry Average Movement | 10.0% |
Market Average Movement | 6.1% |
10% most volatile stocks in US Market | 16.7% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: NMRA's share price has been volatile over the past 3 months.
Volatility Over Time: NMRA's weekly volatility (10%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2019 | 124 | Henry Gosebruch | www.neumoratx.com |
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer’s disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders.
Neumora Therapeutics, Inc. Fundamentals Summary
NMRA fundamental statistics | |
---|---|
Market cap | US$1.47b |
Earnings (TTM) | -US$235.92m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-6.3x
P/E RatioIs NMRA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
NMRA income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$0 |
Gross Profit | US$0 |
Other Expenses | US$235.93m |
Earnings | -US$235.92m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -1.48 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0% |
How did NMRA perform over the long term?
See historical performance and comparison